Clinical Trial Update: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy and safety of Sofosbuvir/Velpatasvir fixed-dose combination with and without Ribavirin in adults with chronic gen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ribavirin (ribavirin)
• Sofosbuvir/Velpatasvir (sofosbuvir/velpatasvir)
• Sofosbuvir/Velpatasvir Fixed Dose Combination (sofosbuvir/velpatasvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C Virus Infection | Phase 2 | Status: COMPLETED | Results posted: 2018-10-30